A Beacon of Innovation and Resilience in Biotech's Challenging Landscape This article provides an overview of the recent grand opening of ChemPartner’s Boston R&D Center of Excellence, written for the broader global scientific community who may not have been able...
ChemPartner brings awareness about Autoimmune & Autoinflammatory Arthritis on 2025 AiArthritis Day Invisible and misunderstood: how it is to live with an autoimmune disease? “I think the hardest part of having an autoimmune...
Three-decade long saga brings promise and breakthrough for better therapies Kirsten rat sarcoma (KRAS) has been long recognized as the most commonly mutated protooncogene, and under active exploration in cancer research for the...
Antibody-drug conjugates (ADCs) are complex therapeutics that link antibodies to cytotoxic payloads, offering a targeted approach to mitigate the systemic toxicity of conventional chemotherapy. Despite rapid progress in ADC engineering, significant challenges remain,...
Unlocking the Potential of Targeted Protein Degradation In the realm of novel therapeutics, targeted protein degradation has serendipitously emerged as a game-changer, transforming "undruggable" proteins into viable candidates for therapeutic intervention. By...
Homing in on the tumor: the magic bullet of cancer therapy Antibody-drug conjugates (ADCs) have revolutionized oncotherapy, achieving significant clinical success in multiple cancer types. Hailed as a “magic bullet” of precision medicine, ADCs improved therapeutic...
Psoriasis: Patient Impact and the Path to Innovation Psoriasis is more than a skin condition, it is often a lifelong, systemic autoimmune disease that may increase the risk of other serious health complications such as heart disease and diabetes, and have a...
Multispecific ADCs: Solutions to Oncology's Toughest Hurdles Antibody drug conjugates (ADCs) combine carefully engineered monoclonal antibodies with chemotherapy drugs, allowing for targeted therapeutic delivery to cancer cells. Targeting tumors with ADCs can mitigate...